The Readout Loud
349: BIO's John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding
Apr 10, 2025
In this engaging conversation, John Crowley, CEO of the industry lobbying group BIO, discusses pressing issues in biotechnology. He sheds light on recent FDA layoffs and the implications for vaccine approval, particularly regarding Novavax's COVID-19 vaccine. Crowley addresses the critical need for a $15 billion federal investment to bolster U.S. biotech against competition from China. He also touches on the complexities surrounding public trust in science, the impact of tariffs on the industry, and how to navigate dialogues with controversial figures like RFK Jr.
40:55
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- John Crowley emphasizes the need for policy reforms in the biotech sector to promote innovation while ensuring public safety amidst regulatory hurdles.
- The impending tariffs on pharmaceutical imports threaten the biotech industry by risking supply chain disruptions and increasing costs, necessitating urgent legislative support.
Deep dives
Current Challenges in Biotech Policy
The biotech industry is currently facing significant challenges due to political changes, impacting essential regulatory bodies like the FDA. John Crowley, the CEO of Bio, emphasizes that much of the industry's anxiety stems from policy issues rather than scientific advancements, which are progressing rapidly. He notes a stark contrast between the technological capabilities available today and the regulatory hurdles that can stifle progress. This dichotomy creates a pressing need for organizations like Bio to advocate for thoughtful policy reforms that promote innovation while ensuring public safety.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
